Stoke Therapeutics Inc reports results for the quarter ended in March - Earnings Summary

Stoke Therapeutics

08/05/2023 14:31

* Stoke Therapeutics Inc  STOK.OQ  reported a quarterly
adjusted
loss of 53 cents​​ per share for the quarter ended in March. The
mean expectation of ten analysts for the quarter was for a loss
of 69 cents per share.
    * Revenue rose 71.7% to $5.15 million from a year ago;
analysts
expected $3.00 million. 
    * Stoke Therapeutics Inc's reported EPS for the quarter was
a loss
of 53 cents​.
    * The mean earnings estimate of analysts had risen by
about 3.1%
in the last three months.​ 
    * In the last 30 days, there have been no negative revisions
of
earnings estimates 
    * Stoke Therapeutics Inc shares had risen by 43.5% this
quarter and gained 29.5% so far this year.
    * The company reported a quarterly loss of $22.55 million.
    * Wall Street's median 12-month price target for Stoke
Therapeutics Inc is $25.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 10 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data May
8 at 01:30 p.m. UTC. ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2023      -0.69          -0.53          Beat
 Dec. 31 2022      -0.70          -0.65          Beat
 Sep. 30 2022      -0.68          -0.66          Beat
 Jun. 30 2022      -0.69          -0.63          Beat